Securian Asset Management Inc. Sells 11,352 Shares of Amgen Inc. $AMGN

Securian Asset Management Inc. lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 43.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,642 shares of the medical research company’s stock after selling 11,352 shares during the quarter. Securian Asset Management Inc.’s holdings in Amgen were worth $4,792,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Dogwood Wealth Management LLC increased its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Board of the Pension Protection Fund bought a new stake in Amgen during the fourth quarter worth about $26,000. Manning & Napier Advisors LLC raised its holdings in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new stake in Amgen during the fourth quarter worth about $33,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of AMGN opened at $331.70 on Monday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a 50 day moving average price of $355.12 and a two-hundred day moving average price of $341.81. The firm has a market capitalization of $179.01 billion, a P/E ratio of 23.08, a P/E/G ratio of 3.33 and a beta of 0.44. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the business earned $4.90 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts forecast that Amgen Inc. will post 22.36 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 70.15%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a report on Tuesday, January 20th. Piper Sandler raised their target price on Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Daiwa Securities Group raised their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a research report on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $357.12.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.